VA Committee

Thursday, September 18 • 5:00 - 6:30 PM CT • Water Tower (Concourse Level)

Agenda

- A. Introductions and Opening Comments Stephen Bartlett, RPh, MSPH
- B. Active Studies for VA Consideration
 - S2114, "A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma" - Dr. Helen Ma, Tibor Rubin VA Medical Center, VA Liaison, Lymphoma Committee
 - 2. <u>S2207</u>, "A Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma" Dr. Helen Ma, Tibor Rubin VA Medical Center, VA Liaison, Lymphoma Committee

C. VA Disease Committee Liaisons

- 1. Updates, Ongoing Goals
 - New VA Liaison; In-person VA Liaison meeting
 Dr. Jessica D. McDermott, Rocky Mountain Regional VA Medical Ctr
- 2. Open Committee Roles

Cancer Care Delivery Immunotherapeutics Lung

Melanoma Palliative Care Prevention, Screening, & Surveillance

How to Apply - <u>vamember@swog.org</u>

D. Current VA Stats

Accrual/sites – SWOG Report

E. Other

- 1. 'All-call' -- seeking interested parties for VA Committee Co-Chair position!
- 2. "Close to Me" funded program that provides cancer care/chemo infusions at several VA community clinics
- 3. Centralization of required VA reviews

F. Future Meetings

- 1st Qtr. 2026 Virtual VA Committee Meeting February 10, 2026, 2:00-3:00pm CT
- SWOG Spring 2026 Group Meeting April 30-May 2, 2026, San Francisco, CA

